News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Sagopilone, a microtubule stabilizer for the potential treatment of cancer.


Posted on: 11/30/2009

Curr Opin Investig Drugs. 2009 Dec;10(12):1359-1371.
Sagopilone, a microtubule stabilizer for the potential treatment of cancer.
Galmarini CM.
UMR 5239, UFR de Médicine Lyon-Sud, 165 Chemin du Grand Revoyet, BP 12, 69921 Oullins, France. cmgalma@hotmail.com.

Sagopilone (ZK-EPO), under development by Bayer Schering Pharma AG, is a novel, fully synthetic epothilone B analog that is representative of a new class of microtubule-stabilizing agents that have a similar mechanism of action to taxanes, but have a decreased propensity for drug resistance. In preclinical studies, sagopilone inhibited cell growth in a wide range of human cancer cell lines. Moreover, sagopilone was not recognized by multidrug-resistant (MDR) cellular efflux mechanisms, and maintained its activity in MDR tumor models. Phase I clinical trials established that the sagopilone side-effect profile was similar to that reported for taxanes, with neuropathy and neutropenia being the most commonly reported toxicities. Initial reports revealed that sagopilone was clinically active in advanced ovarian cancer, advanced melanoma and metastatic chemotherapy-naïve castration-resistant prostate cancer. In contrast, clinical activity demonstrated by sagopilone in NSCLC or metastatic breast cancer was similar to, or less than, the clinical activity observed with other, more clinically advanced epothilones. At the time of publication, sagopilone was being investigated in a broad phase II clinical trial program, including in patients with glioblastoma, NSCLC, melanoma, and small-cell lung, prostate, ovarian and breast cancers.
 
 PMID: 19943207 [PubMed - as supplied by publisher]
 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740